KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Cash & Equivalents (2016 - 2025)

Astrana Health's Cash & Equivalents history spans 16 years, with the latest figure at $339.7 million for Q2 2025.

  • For Q2 2025, Cash & Equivalents rose 4.42% year-over-year to $339.7 million; the TTM value through Jun 2025 reached $339.7 million, up 4.42%, while the annual FY2024 figure was $288.5 million, 1.82% down from the prior year.
  • Cash & Equivalents for Q2 2025 was $339.7 million at Astrana Health, up from $258.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $348.0 million in Q3 2024 and bottomed at $177.3 million in Q2 2021.
  • The 5-year median for Cash & Equivalents is $274.3 million (2023), against an average of $266.5 million.
  • The largest annual shift saw Cash & Equivalents surged 154.51% in 2021 before it decreased 22.78% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $233.1 million in 2021, then grew by 23.57% to $288.0 million in 2022, then rose by 2.01% to $293.8 million in 2023, then dropped by 1.82% to $288.5 million in 2024, then increased by 17.77% to $339.7 million in 2025.
  • Per Business Quant, the three most recent readings for ASTH's Cash & Equivalents are $339.7 million (Q2 2025), $258.5 million (Q1 2025), and $288.5 million (Q4 2024).